Feature | November 05, 2012

Sapien Valve Survival Benefit Widens Further at Three Years

Three-year TAVR data shared at TCT 2012

Edwards Sapien Valve Partner Clinical Trial Heart Valve Repair

November 5, 2012 — Edwards Lifesciences Corporation announced three-year results of a pivotal clinical study of inoperable patients with severe aortic stenosis treated with the Edwards Sapien transcatheter heart valve. The data from The PARTNER Trial (Cohort B) demonstrated a sustained and increasing survival benefit for Sapien valve patients at three years, as well as significantly less time spent in the hospital. The new results were presented at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

The three-year all-cause mortality rate for transcatheter aortic valve replacement (TAVR) patients was 54.1 percent, as compared to 80.9 percent for those patients receiving standard therapy. Despite the advanced age and comorbidities of this inoperable patient population, the mortality rates in the third year of follow-up were 19.3 percent for TAVR patients and 40.3 percent for control. Also of note, TAVR patients experienced a median period of time out of the hospital that was more than two-and-a-half times longer than that of standard therapy patients.

There was a higher stroke rate in the transcatheter group as compared to standard therapy, although the two additional events between the second and third years of follow-up were adjudicated to not be related to the procedure or the device.

"We are very pleased that the inoperable patients in The PARTNER Trial continued to experience benefits in all the key measures of clinical outcomes. The performance and durability of the Edwards Sapien valve also remained excellent," said Michael A. Mussallem, Edwards' chairman and CEO. "The three-year data further highlight the devastating effects of symptomatic severe aortic stenosis in patients receiving only standard therapy — reinforcing the important role that transcatheter valve replacement plays in the treatment of these patients."

This trial studied 358 patients with severe, symptomatic aortic stenosis deemed inoperable for traditional open-heart surgery. Patients were evenly randomized to receive either the Sapien valve or standard therapy. The U.S Food and Drug Administration (FDA) approved the Sapien valve in November 2011 for the treatment of inoperable patients, and also approved Sapien for high-risk surgical patients.

For more information: www.edwards.com

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init